A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
The current price of AstraZeneca PLC in the market is ₩300,457.12, with a 24-hour trading volume of ₩343.14B. The asset's market cap is ₩465.95T, after moving 2.16% in the last day.
Tokenized AstraZeneca PLC is trading at ₩151,659.56, with a tokenized market cap of ₩20.77B and a 24-hour trading volume of ₩978.44M. The tokenized asset has moved 0.21% in the past 24 hours.